Enanta Pharmaceuticals Stock Today

ENTA Stock  USD 14.71  1.11  7.02%   

Performance

4 of 100

 
Weak
 
Strong
Insignificant

Odds Of Distress

Less than 17

 
High
 
Low
Low
Enanta Pharmaceuticals is trading at 14.71 as of the 19th of July 2024, a 7.02 percent decrease since the beginning of the trading day. The stock's open price was 15.82. Enanta Pharmaceuticals has less than a 17 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Enanta Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 19th of June 2024 and ending today, the 19th of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
21st of March 2013
Category
Healthcare
Classification
Health Care
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts. The company has 21.18 M outstanding shares of which 3.01 M shares are currently shorted by private and institutional investors with about 14.57 trading days to cover. More on Enanta Pharmaceuticals

Moving against Enanta Stock

  0.38MRK Merck Company Financial Report 6th of August 2024 PairCorr
  0.34ZURA Zura Bio LimitedPairCorr
  0.33PTCT PTC TherapeuticsPairCorr

Enanta Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO and President and DirectorJay Luly
Thematic IdeaTrump Equities (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Trump Equities, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.190.2
Notably Down
Slightly volatile
Gross Profit Margin0.780.87
Moderately Down
Slightly volatile
Total Current Liabilities75.8 M72.2 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total220.7 M210.2 M
Sufficiently Up
Slightly volatile
Total Assets327.6 M531.6 M
Way Down
Slightly volatile
Total Current Assets270.6 M486.2 M
Way Down
Slightly volatile
Debt Levels
Enanta Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Enanta Pharmaceuticals' financial leverage. It provides some insight into what part of Enanta Pharmaceuticals' total assets is financed by creditors.
Liquidity
Enanta Pharmaceuticals currently holds 26.51 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Enanta Pharmaceuticals has a current ratio of 13.32, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Enanta Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Change To Inventory

(13.94 Million)
Enanta Pharmaceuticals (ENTA) is traded on NASDAQ Exchange in USA. It is located in 500 Arsenal Street, Watertown, MA, United States, 02472 and employs 145 people. Enanta Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 311.55 M. Enanta Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 21.18 M outstanding shares of which 3.01 M shares are currently shorted by private and institutional investors with about 14.57 trading days to cover. Enanta Pharmaceuticals currently holds about 253.29 M in cash with (103.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.22.
Check Enanta Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
The majority of Enanta Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Enanta Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Enanta Pharmaceuticals. Please pay attention to any change in the institutional holdings of Enanta Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Enanta Ownership Details

Enanta Stock Institutional Holders

InstituionRecorded OnShares
Assenagon Asset Management Sa2024-03-31
583.7 K
Soleus Capital Management, L.p.2024-03-31
580.5 K
D. E. Shaw & Co Lp2024-03-31
570.2 K
Renaissance Technologies Corp2024-03-31
526.1 K
Bank Of America Corp2024-03-31
516.4 K
Geode Capital Management, Llc2024-03-31
442.1 K
State Street Corporation2024-03-31
424 K
Boothbay Fund Management, Llc2024-03-31
388.6 K
Tang Capital Management Llc2024-03-31
300 K
Farallon Capital Management, L.l.c.2024-03-31
2.1 M
Morgan Stanley - Brokerage Accounts2024-03-31
M
View Enanta Pharmaceuticals Diagnostics

Enanta Pharmaceuticals Historical Income Statement

At present, Enanta Pharmaceuticals' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 104.9 M, whereas Depreciation And Amortization is forecasted to decline to about 1.9 M. View More Fundamentals

Enanta Stock Against Markets

Enanta Pharmaceuticals Corporate Management

Nathaniel JDGeneral VPProfile
Scott MDSenior OfficerProfile
Nathalie MDConsultantProfile
Jennifer VieraSenior CommunicationsProfile
Tara KiefferSenior DevelopmentProfile
Brendan LuuSenior DevelopmentProfile

Additional Information and Resources on Investing in Enanta Stock

When determining whether Enanta Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enanta Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enanta Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enanta Pharmaceuticals Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.66)
Earnings Share
(6.25)
Revenue Per Share
3.455
Quarterly Revenue Growth
(0.04)
Return On Assets
(0.23)
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.